ValiRx Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Mark Eccleston
Chief executive officer
UK£83.4k
Total compensation
| CEO salary percentage | 25.13% |
| CEO tenure | 1.6yrs |
| CEO ownership | 7.9% |
| Management average tenure | no data |
| Board average tenure | 2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -UK£2m |
| Mar 31 2025 | n/a | n/a | -UK£2m |
| Dec 31 2024 | UK£83k | UK£21k | -UK£2m |
Compensation vs Market: Mark's total compensation ($USD111.65K) is below average for companies of similar size in the German market ($USD387.39K).
Compensation vs Earnings: Insufficient data to compare Mark's compensation with company performance.
CEO
Mark Eccleston (54 yo)
Dr. Mark Eccleston, Ph.D. & M.B.A. serves as Member of Commercial Advisory Board at ValiRx plc and serves as its Member of Scientific Advisory Board also serves as it's CEO since August 12, 2024 and also s...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Director | no data | UK£83.38k | 7.91% € 227.0k | |
| CFO, Company Secretary & Executive Director | 19.8yrs | UK£66.45k | 0.29% € 8.4k | |
| Member of Commercial Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Advisory Board | 1yr | no data | no data | |
| Independent Non-Executive Chairman | 1.9yrs | UK£26.27k | 0.27% € 7.6k | |
| Member of Advisory Board | 1yr | no data | no data | |
| Chair of Advisory Board & Non Executive Director | 3.2yrs | UK£29.05k | 0.27% € 7.9k | |
| Board observer | 2yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: EAJF's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/07 16:49 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ValiRx plc is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Donnellan | Cavendish |
| Andrew Edmond | Equity Development Limited |
| Gregoire Pave | Hardman & Co. |